Search Results for: I

NEWS

EVENTS Upcoming Events Past Events

CORPORATE GOVERNANCE Documents & Charters Audit Committee Charter Compensation Committee Charter Nominating & Corporate Governance Committee Charter Code of Business Conduct & Ethics Corporate Governance Guidelines Other Links View Our Management View Our Board of Directors Committee Composition Audit Compensation Nominating and Corporate Governance Committee Daniel Zabrowski Chair Member Roger Sawhney Member Member Amy Ronneberg

FAQs Corporate FAQs Where is Actuate headquartered? Our corporate headquarters is in Fort Worth, Texas How is Actuate stock traded? Our shares are traded on NASDAQ Global Market under the stock symbol ACTU When was Actuate incorporated? Actuate was incorporated on January 16, 2015 When did Actuate go public? Actuate went public on August 13,

CONTACT US If you would like to partner with us, have media inquiries, or simply want to learn more, we want to hear from you. Fill out the form below to get in touch. US ADDRESS 1751 River Run, Suite 400 Fort Worth, TX 76107 EMAIL info@actuatetherapeutics.com EU ADDRESS The Black Church St. Mary’s Place

CAREERS We are pushing further, discovering more, and redefining treatment expectations for patients and providers. But as passionate as we are about our work, we’re equally passionate about doing everything with integrity, ethics, and inclusion. Careers We live, breathe, and sleep scientific innovation. It’s the “why” behind everything we do. If you are driven by

ABOUT US Our focus on glycogen synthase kinase-3β (the enzyme GSK-3β) has led to the development of the therapeutic candidate elraglusib (formerly known as 9-ING-41). Elraglusib has shown tremendous potential in the treatment of many different cancers when used alone or in combination with other types of cancer therapies, including chemotherapy and immune modulators such

THE PASSION TO PURSUE MORE Who we are Actuate aims to give patients with hard-to-treat cancers the opportunity to live longer and better with the potential capacity to slow, stop, or shrink tumors, with minimal adverse effects. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets multiple molecular pathways in cancer that are involved in promoting